Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA), taking place June 20-23, 2025, in Chicago, IL. The presentations will highlight the breadth of the companies' metabolic disease portfolio, including data from several clinical-stage injectable and oral therapies. Data presented will cover results from clinical trials sponsored and conducted by Hengrui for an injectable GLP-1/GIP receptor dual agonist HRS9531 (in development as KAI-9531 outside of Greater China), an oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535), and an oral formulation of HRS9531 (KAI-9531).
The following abstracts were submitted by Hengrui and accepted for presentation:
HRS9531Oral presentation: Friday, June 20, 5:45-6:00 p.m. CT
Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks
Abstract 126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
Posters: Sunday, June 22, 12:30-1:30 p.m. CT
Phase 1 clinical trial of HRS9531 (oral peptide) in healthy participants
Abstract 797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study
Phase 2 clinical trial of HRS9531 in adults with obesity without diabetes up to 52 weeks
Abstract 853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment
Phase 2 clinical trial of HRS9531 high dose (8 mg) in adults with obesity or overweight without diabetes
Abstract 874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes
HRS-7535Posters: Sunday, June 22, 12:30-1:30 p.m. CT
Phase 2 clinical trial of HRS-7535 in adults with type 2 diabetes
Abstract 837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin
Phase 2 clinical trial of HRS-7535 in adults with obesity without diabetes
Abstract 865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes
All abstracts will be published online in the journal Diabetes® and presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ADA website.
About Hengrui PharmaJiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.
About Kailera TherapeuticsKailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com and follow us on LinkedIn and X.
Contact Information for Hengrui PharmaDGA Grouphengrui@dgagroup.com
Contact Information for KaileraMaura GavaghanVice President, Corporate Communications and Investor Relationsmaura.gavaghan@kailera.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
22 minutes ago
- Business Wire
CDB Aviation and Loong Air Execute Lease Agreements for Six A321neo Aircraft
HANGZHOU, China--(BUSINESS WIRE)--CDB Aviation, a wholly owned Irish subsidiary of China Development Bank Financial Leasing Co., Ltd. ('CDB Leasing'), announced the execution of new lease agreements for six Airbus A321neo aircraft with its Chinese airline customer, Zhejiang Loong Airlines Co., Ltd. ('Loong Air'). We are pleased to strengthen our partnership with Loong Air through this transaction, which underscores our commitment to supporting the growth of China's aviation sector. Share The Hangzhou-headquartered carrier is expected to take delivery of the aircraft in 2027 from the lessor's orderbook. Renowned for its fuel efficiency, reduced carbon emissions, and extended range capabilities, the A321neo, the largest member of Airbus' A320neo family, is well suited to enhance Loong Air's operational efficiency and sustainability goals. 'We are pleased to strengthen our partnership with Loong Air through this transaction, which underscores our commitment to supporting the growth of China's aviation sector,' said Jie Chen, Chief Executive Officer of CDB Aviation. 'The A321neo's superior economics and passenger comfort align perfectly with Loong Air's vision of expanding its domestic, international and regional network.' Established in 2011, Loong Air operates a fleet of over 70 Airbus A320-family aircraft, serving major Chinese cities and select international routes. The addition of the A321neos will enable the airline to boost capacity on high-demand routes while maintaining its focus on cost efficiency and environmental responsibility. 'This agreement marks another milestone in Loong Air and CDB Aviation's strategic partnership of more than 10 years,' commented Qihong Liu, Chairman of Loong Air. 'We also hope to continue to explore new opportunities of cooperation with CDB Aviation and jointly promote innovative development in the future. The A321neo's enhanced performance and cabin flexibility will allow us to offer an elevated travel experience to our passengers, while supporting our long-term sustainability objectives.' Forward-Looking Statements This press release contains certain forward-looking statements, beliefs or opinions, including with respect to CDB Aviation's business, financial condition, results of operations or plans. CDB Aviation cautions readers that no forward-looking statement is a guarantee of future performance and that actual results or other financial condition or performance measures could differ materially from those contained in the forward-looking statements. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements sometimes use words such as 'may,' 'will,' 'seek,' 'continue,' 'aim,' 'anticipate,' 'target,' 'projected,' 'expect,' 'estimate,' 'intend,' 'plan,' 'goal,' 'believe,' 'achieve' or other terminology or words of similar meaning. These statements are based on the current beliefs and expectations of CDB Aviation's management and are subject to significant risks and uncertainties. Actual results and outcomes may differ materially from those expressed in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events or otherwise. About Loong Air Zhejiang Loong Airlines Co., Ltd. ('Loong Air') was established on April 19, 2011, with its first cargo flight launched on August 9, 2012, and its first passenger flight on December 29, 2013, Based on Hangzhou, Zhejiang Province. The company serves as Zhejiang Province's leading home-based airline and one of the key players in the aviation industry. Loong Air has established three branches in Northwest, Southwest, and Central-South of China. To date, its fleet size reach to 73, operating domestic and international passenger and cargo routes covering Mainland China, Hong Kong, Macau and extending to Japan, South Korea, Southeast Asia, South Asia, and Central Asia, transporting over 10 million passengers annually. The company is committed to four major development visions: high-quality, group operations, intelligence and international, to establish itself as a world-class aviation group. About CDB Aviation CDB Aviation is a wholly owned Irish subsidiary of China Development Bank Financial Leasing Co., Ltd. ('CDB Leasing') a 40-year-old Chinese leasing company that is backed mainly by the China Development Bank. CDB Aviation is rated Investment Grade by Moody's (A2), S&P Global (A), and Fitch (A+). China Development Bank is under the direct jurisdiction of the State Council of China and is one of the world's largest development finance institution. It is also the largest Chinese bank for foreign investment and financing cooperation, long-term lending and bond issuance, enjoying Chinese sovereign credit rating. CDB Leasing is the only leasing arm of the China Development Bank and a leading company in China's leasing industry that has been engaged in aircraft, infrastructure, ship, commercial vehicle and construction machinery leasing and enjoys a Chinese sovereign credit rating. It took an important step in July 2016 to globalize and marketize its business – listing on the Hong Kong Stock Exchange (HKEX STOCK CODE: 1606).

Epoch Times
23 minutes ago
- Epoch Times
When the Clock Ticks Too Early: How TCM Offers Hope for Premature Ovarian Failure
Many young women today experience the annoyance of irregular menstruation, reduced menstrual blood volume, missed periods, fatigue, hair thinning, low libido, and mood swings. Some even find themselves unable to conceive when they're ready to start a family. A diagnosis usually reveals a premature ovarian failure. This condition involves a decline in ovarian function before the age of 40 and can drastically affect fertility, hormone balance, and overall well-being. In traditional Chinese medicine (TCM), premature ovarian failure is seen as a result of underlying constitutional imbalances—particularly involving the kidneys, spleen, and liver. Rather than focusing solely on the ovaries, TCM aims to rebalance the entire body. By nourishing the kidneys, which govern reproduction; strengthening the spleen, which supports blood and energy production; and smoothing liver 'qi,' or energy flow that regulates menstruation, TCM works to restore ovarian function and improve reproductive health from the inside out. Understanding the Root Causes in TCM Generally, women stop menstruating naturally around the age of 50, but patients with premature ovarian failure may begin to experience menopausal symptoms such as hot flashes, night sweats, palpitations, hair loss, and insomnia between the ages of 20 and 30. These symptoms can have a significant effect on both the body and mind.


Business Upturn
an hour ago
- Business Upturn
RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Why is RxSight being Investigated? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619